| abstract |
HYDROXAMIC ACID DERIVATIVES - The present invention provides hydroxamic acid derivatives of the formula wherein R1 is 1-7C alkyl; R2 represents hydrogen, 1-6C alkyl or a group of the formula - (CH2) n-aryl or - (CH2) n-het, in which n has a value of 1-4 het represents a 5- or 6-membered N-heterocyclic ring. which (a) is bonded via N atoms, (b) optionally contains N, O and / or S as additional hetero atoms in a position not adjacent to the bonding N atom, (c) is replaced by oxo at one or both C atoms. adjacent to the N bond atom and (d) optionally bonded with a benz bond or optionally substituted on one or more C atoms with 1-6C alkyl or oxo and / or on any additional N atom with a 1-6C alkyl group; R3 represents a characteristic group of natural or artificial alpha-amino acid, in which any functional group present can be protected, provided that R3 is not hydrogen; R 4 represents carboxyl, (1-6C alkoxy) carbonyl, carbamoyl or (1-6C alkyl) carbamoyl; R5 represents a characteristic group of natural alpha-amino acid in which any functional group present can be protected; and R 6 represents hydrogen; or R4, R5 and R6 each individually represent hydrogen or (1-6C) alkyl and their pharmaceutically acceptable salts, which are inhibitors of matrix metalloproteinase useful for controlling or preventing degenerative joint diseases such as rheumatic arthritis and osteoarthritis Ui for the treatment of invasions tumors, atherosclerosis, or multiple sclerosis. They can be produced according to generally known methods by deprotecting the new benzyloxyamino compound or hydrogenating the corresponding new amino acid or its activated derivative. |